Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

BlueWillow Biologics

BlueWillow Biologics?uq=UG6efJS6
2000 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Series A LATEST DEAL TYPE
$10M LATEST DEAL AMOUNT
11 INVESTORS
Description

Developer of vaccines designed to prevent respiratory diseases and offer mucosal immunity. The company's vaccines are developed with adjuvant technology that identifies both systemic and mucosal immune responses, enabling health care providers to protect people from severe respiratory and sexually transmitted diseases that enter inside the body through mucosal surfaces.

Formerly Known As
NanoBio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
  • 2311 Green Road
  • Ann Arbor, MI 48105
  • United States

+1 (734) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore BlueWillow Biologics’s full profile, request a free trial.

BlueWillow Biologics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series A) 07-May-2018 $10M 000.00 0000 Completed Generating Revenue
10. Grant 06-Mar-2017 00.00 000.00 Completed Generating Revenue
9. Grant 29-Oct-2013 00.00 000.00 Completed Generating Revenue
8. Later Stage VC (Series C) 28-Nov-2012 0000 000.00 000.00 Completed Generating Revenue
7. Grant 30-Nov-2010 000 000.00 Completed Generating Revenue
6. Later Stage VC (Series B) 29-May-2009 000.00 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series A) 06-Mar-2008 0000 0000 000.00 Completed Generating Revenue
4. Early Stage VC 11-May-2005 00.000 00.000 Completed Generating Revenue
3. Angel (individual) 11-Oct-2004 $2.16M $4.09M Completed Generating Revenue
2. Angel (individual) 12-Apr-2002 $1.93M $1.93M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

BlueWillow Biologics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A1 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

BlueWillow Biologics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Institute Of Allergy and Infectious Diseases Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
Centre Lane Partners PE/Buyout Minority 000 0000 000000 0
Grand Angels Angel Group Minority 000 0000 000000 0
Line Moon Ventures Other Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

BlueWillow Biologics Executive Team (10)

Name Title Board
Seat
Contact
Info
David Peralta Chief Executive Officer & Board Member
Susan Ciotti Ph.D Director, Formulations
Douglas Smith Director, Immunology
Stephen Gracon Regulatory Consultant
Ali Fattom Ph.D Senior Vice President, Vaccine Research & Development

5 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

BlueWillow Biologics Board Members (11)

Name Representing Role Since Contact
Info
Chad Costley Self Board Member 000 0000
David Peralta BlueWillow Biologics Chief Executive Officer & Board Member 000 0000
David Stout Self Board Member 000 0000
Gary Costley Ph.D Self Board Member 000 0000
Hugo Braun North Coast Technology Investors Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »